Abstract
One of the basic challenges in bone biology is to identify and understand the mechanisms by which specific molecules regulate cell proliferation, differentiation and cell-cell interactions between bone-forming osteoblasts and bone-resorbing osteoclasts which occur throughout life during normal modeling and remodeling. In recent years, many molecules have been identified which, through very different mechanisms of action, control the balance between formation and resorption. These include for example, cytokines, signaling molecules, receptors, systemic hormones and transcription factors, and these have been roughly mapped to the putative sites of action (Fig. 1). Indeed, each of these molecules are important since alterations in the expression of many of them form the basis of developmental bone defects, metabolic bone disease and skeletal neoplasias. It can be reasoned that the large number of factors which have been identified to date make it unlikely that a single mechanism alone will explain the molecular basis of bone remodeling. Rather, the intricate control of bone remodeling will likely be due to a combination of factors, some of which share target cells and pathways and others which interact indirectly. Thus, while the large number of factors increase the complexity of this system, they also serve to expand the number of potential targets for intervention.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell- proliferation and transformation. Biochim Biophys Acta 1072: 129 - 157
Balsabore A, Jolicoeur P (1995) Fos proteins can act as negative regulators of cell growth independently of the fos transforming pathway. Oncogene 11: 455 - 465
Brüsselbach S, Möhle-Steinlein U, Wang Z-Q, Schreiber M, Lucibello FC, Müller R, Wagner EF (1995) Cell proliferation and cell cycle progression are not impaired in fibroblasts and ES cells lacking c-Fos. Oncogene 10: 79 - 86
Elledge SJ, Winston J, Harper JW (1996) A question of balance - the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol 6: 388 - 392
Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766 - 1769
Grigoriadis AE, Schellander K, Wang Z-Q, Wagner EF (1993) Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122: 685 - 701
Grigoriadis AE, Wang Z-Q, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF (1994) c-Fos is a key regulator of osteoclast/macrophage lineage determination and bone remodeling. Science 266: 443 - 448
Grigoriadis AE, Wang Z-Q, Wagner EF (1995) Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet 11: 436 - 441
Harper JW, Elledge SJ (1996) CDK inhibitors in development and cancer. Curr Opin Genet Devel 6: 56 - 64
Hoyland J, Sharpe PT (1994) Up-regulation of c-Fos protooncogene expression in pagetic osteoclasts. J Bone Mineral Res 9: 1191 - 1194
Hunter T, Pines J (1994) Cyclins and cancer. Il. Cyclin-D and CDK inhibitors come of age. Cell 79: 573-582
Kobayashi K, Phuchareon J, Inada K, Tomita Y, Koizumi T, Hatano M, Miyatake S, Tokuhisa T (1997) Overexpression of c-fos inhibits down-regulation of a cyclin-dependent kinase-2 inhibitor p27(Kipl) in splenic B cells activated by surface Ig cross-linking. J Immunol 158: 2050 - 2056
Lang Z, Feingold JM (1996) An autonomously replicating eukaryotic expres- sion vector with a tetracycline-responsive promoter. Gene 168: 169 - 171
Maelandsmo GM, Berner J-M, Florenes VA, Forus A, Hovig E, Fodstad O, Myklebost 0 (1995) Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - relationship to amplification and messenger RNA levels of CDK4 and CCND1. Brit J Cancer 72: 393 - 398
Masuda H, Miller C, Koeffler HP, Battiflora H, Cline MJ (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84: 7716 - 7719
Miao GG, Curran T (1994) Cell transformation by c-Fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 14: 4295 - 4310
Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, Arnold A (1991) A novel cyclin encoded by a BCLI -linked candidate oncogene. Nature 350: 512 - 515
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Clearly K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705 - 708
Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J-A, Kushner P, Scanlan TS (1997) Differential ligand activation of estrogen receptors ERa and ER(3 at APl sites. Science 277: 1508 - 1510
Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M (1996) Oncogene alterations in primary, recurrent and metastatic human bone tumors. J Cell Biochem 63: 37 - 50
Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G(1) cyclin-dependent kinases. Genes Dev 9: 1149 - 1163
Smith E, Frenkel B, Schlegel R, Giordano A, Lian JB, Stein LL, Stein GS (1995) Expression of cell cycle regulatory factors in differentiating osteoblasts — postproliferative up-regulation of cyclin-B and cyclin-E. Cancer Res 55: 5019 - 5024
Sunters A, McCluskey J, Grigoriadis AE (1998) Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation. Devel Genet 22: 386 - 397
Wang Z-Q, Liang J, Schellander K, Wagner EF, Grigoriadis AE (1995) c-Fosinduced osteosarcoma formation in transgenic mice: Cooperativity with c-Jun and the role of endogenous c-Fos. Cancer Res 55: 6244-6251
Wang Z-Q, Ovitt C, Grigoriadis AE, Möhle-Steinlein U, Rüther U, Wagner, EF (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360: 741 - 745
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323 - 330
Wu J-X, Carpenter PM, Gresens C, Keh R, Niman H, Morris JWS, Mercola D (1990) The proto-oncogene c-Fos is overexpressed in the majority of human osteosarcomas. Oncogene 5: 989 - 1000
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Grigoriadis, A.E., Sunters, A. (1998). The Regulation of Bone Cell Differentiation and Proliferation by Transcription Factors. In: Russell, R.G.G., Skerry, T.M., Kollenkirchen, U. (eds) Novel Approaches to Treatment of Osteoporosis. Ernst Schering Research Foundation Workshop, vol 25. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09007-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-662-09007-7_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-09009-1
Online ISBN: 978-3-662-09007-7
eBook Packages: Springer Book Archive